[Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone]
Related Experiment Videos
Sangre
|January 1, 1984
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Linking redox and calcium signaling via thioredoxins.
Journal of experimental botany·2025
Risk-adapted intensification therapy in high-risk prostate cancer: how relevant is the role of radiation dose.
Radiation oncology (London, England)·2025
The impact of a multidisciplinary approach on treatment decisions and outcomes in urothelial carcinoma: A systematic review.
Actas urologicas espanolas·2025
Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.
Actas urologicas espanolas·2024
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper.
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
[MLL rearrangements in acute leukemias].
Sangre·2000
Enzalutamide alone or combined with other pharmacologic agents for metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Nivolumab dose stewardship in routine Oncology practice: a real-world health-economic simulation.
Expert review of pharmacoeconomics & outcomes research·2026
Impact of the Multimodal Protocol on the Outcomes of Cancer Patients Undergoing Radical Cystectomy.
Revista do Colegio Brasileiro de Cirurgioes·2026
An Optimized Cancer Cachexia Research Model.
Current protocols·2026
Vitamin C for the prevention of complex regional pain syndrome after foot and ankle fractures or surgery: a systematic review.
European review for medical and pharmacological sciences·2026
Macrophages Are Not Welcome: Potential of CCR1/CCR2 Inhibition for Cytokine Release Prevention.
Cancer immunology research·2026